Compare LZM & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | ALT |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | Isle of Man | United States |
| Employees | 93 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.3M | 421.5M |
| IPO Year | N/A | 2005 |
| Metric | LZM | ALT |
|---|---|---|
| Price | $4.30 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $17.67 |
| AVG Volume (30 Days) | 530.9K | ★ 2.6M |
| Earning Date | 03-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $86.37 | N/A |
| Revenue Next Year | $202.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $3.07 | $2.56 |
| 52 Week High | $6.40 | $7.73 |
| Indicator | LZM | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 36.69 |
| Support Level | $4.15 | $2.56 |
| Resistance Level | $4.32 | $4.19 |
| Average True Range (ATR) | 0.38 | 0.12 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 2.33 | 0.00 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.